Cargando…
Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder
Acamprosate is an anti-craving drug used in alcohol use disorder (AUD) pharmacotherapy. However, only a subset of patients achieves optimal treatment outcomes. The identification of predictive biomarkers of acamprosate treatment response in patients with AUD would be a substantial advance in addicti...
Autores principales: | Ho, Ming-Fen, Zhang, Cheng, Moon, Irene, Coombes, Brandon J., Biernacka, Joanna, Skime, Michelle, Choi, Doo-Sup, Croarkin, Paul E., Frye, Mark A., Ngo, Quyen, Skillon, Cedric, Oesterle, Tyler S., Karpyak, Victor M., Li, Hu, Weinshilboum, Richard M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475292/ https://www.ncbi.nlm.nih.gov/pubmed/36120372 http://dx.doi.org/10.3389/fphar.2022.986238 |
Ejemplares similares
-
Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation
por: Ho, Ming-Fen, et al.
Publicado: (2023) -
Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism
por: Ho, Ming-Fen, et al.
Publicado: (2022) -
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
por: Ho, Ming‐Fen, et al.
Publicado: (2022) -
Corrigendum to “Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder” [Drug Alcohol Depend. 243 (2023) 109753]
por: Karpyak, Victor M., et al.
Publicado: (2023) -
TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
por: Ho, Ming-Fen, et al.
Publicado: (2020)